

### **REMARKS**

Claims 1-16, which are subject to a Restriction Requirement, are pending in this application.

### **SEQUENCE REQUIREMENTS**

In compliance with the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures, the Applicants herein direct entry of the corrected Sequence Listing filed herewith in place of the originally filed Sequence Listing.

### **ELECTION/RESTRICTION**


A requirement for restriction has been made under 35 U.S.C. §121 (37 C.F.R. §1.142) between the inventions of:

- I. Claims 1, 4, 13, and 14, drawn to polypeptide ligands for the HFGAN72 receptor;
- II. Claims 2 and 3, drawn to nucleic acids encoding the polypeptide ligands;
- III. Claims 5, 10, and 16, drawn to agonists and methods of treatment using the agonists;
- IV. Claims 6 and 9, drawn to antibodies and methods of treatment using the antibodies;
- V. Claims 7, 8, and 15, drawn to antagonists and methods of treatment using the antagonists;
- VI. Claim 11, drawn methods of screening for agonists; and
- VII. Claim 12, drawn to a method of screening antagonists.

Upon review of the Detailed Action provided by the Examiner, the Applicants provisionally elect the subject matter of Group I, Claims 1, 4, 13, and 14, without traverse.

Should the restriction become final, the Applicants reserve the right to prosecute, in one or more patent applications, the canceled claims, the claims to non-elected inventions, the claims as originally filed, and any other claims supported by the specification.

Respectfully submitted,



Elizabeth J. Hecht  
Attorney for Applicants  
Reg. No. P-41,824

SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Telephone No.:(610) 270-5009  
Facsimile No.:(610) 270-5090